Abnormalities of mineral metabolism occur early in chronic kidney disease. Quantification of the prevalence of these abnormalities has not been described using current assays nor in large unselected populations. This outpatient cohort cross-sectional study was conducted in 153 centers, (71% primary care practices). Blood for parathyroid hormone (PTH), vitamin D metabolites, creatinine, calcium (Ca), and phosphorus (P) were drawn between June and October 2004. Low 1,25-dihydroxyvitamin D (1,25 OH 2 D 3 ) was defined as o22 pg/ml. The 1814 patients had a mean age of 71.1 years old; 48% had diabetes mellitus (DM). Low 1,25 OH 2 D 3 was evident at all estimated glomerular filtration rate (eGFR) levels: 13% in those with eGFR 480 ml/min, 460% in those with eGFR o30 ml/min. High PTH (465pm/dl) occurred in 12% with eGFR 480 ml/min. Serum Ca and P were normal until eGFR was o40 ml/min. Significant differences in the mean and median values of 1,25 OH 2 D 3 , PTH, but not 25(OH)D 3 levels, were seen across deciles of eGFR (Po0.001). Multivariate analysis revealed that DM, increased urinary albumin/creatinine ratio and lower eGFR predicted lower values of 1,25 OH 2 D 3 . A high prevalence of mineral metabolite abnormalities occurs in a large unreferred US cohort. Low 1,25 OH 2 D 3 and elevated PTH are common at higher eGFR than previously described. As bone, cardiovascular disease, and mineral metabolite are correlated; further studies are necessary to determine the importance of these findings relative to outcomes. It is now accepted that the presence of chronic kidney disease (CKD) is associated with poor outcomes.
It is now accepted that the presence of chronic kidney disease (CKD) is associated with poor outcomes. [1] [2] [3] In particular, cardiovascular events and mortality increase as the estimated glomerular filtration rate (eGFR) declines below 60 ml/min. 4 In dialysis patients, cardiovascular disease is 10-to 20-fold higher than the general population, representing at least half of the 15-25% per year mortality rate. 5 The mechanisms associating CKD with mortality have not been determined, in part, owing to the lack of comprehensive clinical and biochemical analyses.
Recently, increased attention has focused on endocrine abnormalities in patients with CKD as a way to explain some of these associations. 6, 7 For example, 1,25-dihydroxyvitamin D (1,25 OH 2 D 3 ) deficiency is known to occur during the progression of CKD because the final hydroxylation step of 25-hydroxyvitamin D (25(OH)D 3 ) to 1,25 OH 2 D 3 (calcitriol) is mediated by kidney 1á-hydroxylase. 8 Calcitriol deficiency plays a major role in the development of secondary hyperparathyroidism (HPTH), as 1,25 OH 2 D 3 deficiency promotes parathyroid gland growth (hyperplasia) and increased parathyroid hormone (PTH) synthesis through loss of the ability to upregulate vitamin D receptor expression within parathyroid cells. 9 The end result is elevated serum PTH and abnormal calcium (Ca) and phosphorus (P) balance.
Elevated PTH and hyperphosphatemia were recently identified again as risk factors for mortality in dialysis patients. 10 However, additional data indicate that vitamin D treatment is an important factor that may mitigate the effects of HPTH and hyperphosphatemia on cardiovascular mortality. 7 These findings not only have practical applications to current dialysis treatment, but they may also have important implications in the much larger population of CKD patients who are not receiving dialysis. Currently, there are also concerns regarding the potential side effects of vitamin D therapy, such as hypercalcemia and vascular calcification. In order to better understand the role of vitamin D in this setting, it is important to first establish the relationship of eGFR to disordered vitamin D and mineral metabolism in the untreated state.
The purpose of this cross-sectional analysis of baseline data available from an observational, prospective study was to determine the relationships of circulating vitamin D, PTH, Ca, and P in CKD patients who were not receiving prescribed vitamin D, as an initial attempt to better identify the role of vitamin D deficiency as it relates to eGFR and the development of HPTH. Figure 1 describes the population screening and inclusion process from which the final cohort for analysis was derived. From June 2004 to October 2004, 5255 patients were screened, and 1903 patients met the entry criteria. Screening failures resulted primarily from the fact that the eGFR values calculated using the most recent serum creatinine in the chart were X60 ml/min/1.73 m 2 . Of the 1903 patients who were enrolled in the Study for the Evaluation of Early Kidney disease (SEEK) study, 89 patients were not included in the analysis because of an inability to calculate an estimated eGFR owing to missing laboratory values for serum creatinine, and thus providing 1814 CKD patients (866 or 48% men and 948 women) with data available for analysis.
RESULTS

Population baseline characteristics
The general characteristics of the patient population are shown in Table 1 . The demographics are displayed by total population, and by level of eGFR, as calculated from the serum creatinine values taken at the baseline visit. Note that the mean eGFR was 47 ml/min, 85% were hypertensive, the majority of patients were 465 years of age (71%), approximately 35% describe a history of some form of coronary artery disease, and 47% were diabetic. The representation of African Americans is similar to that of the US population (12%). Patients were distributed across all geographic regions in the United States with 71% being enrolled from primary care practices, 19% from nephrologists, 7% from endocrinologists, and 3% from cardiologists. Less than 25% of the population was taking Ca supplementation, and less than 10% were on hormone replacement therapy or bisphosphonates. Figure 2 describes the distribution of patients by eGFR intervals. . This was the result of a discrepancy between the eGFR calculated from the screening chart serum creatinine and the eGFR calculated from the serum creatinine measured at baseline (study visit 1).
Gender and ethnicity were not significantly different between subjects with an eGFR of 30 and 60 ml/min/1.73 m 2 when calculated from the screening chart serum creatinine but who had an eGFR of 4 or o60 ml/min/1.73 m 2 when calculated from the serum creatinine measured at baseline. Subjects with an eGFR of 30-60 ml/min/1.73 m 2 when calculated from the screening chart serum creatinine and whose eGFR remained o60 ml/min/1.73 m 2 when calculated from the serum creatinine measured at baseline were significantly older, had significantly lower 1,25 OH 2 D 3 and 25(OH)D 3 levels and significantly higher intact PTH (iPTH) levels compared to those with an eGFR of 30-60 ml/min/ 1.73 m 2 when calculated from the screening chart serum creatinine and whose eGFR was 460 ml/min/1.73 m 2 eGFR when calculated from the serum creatinine measured at baseline.
iPTH, Ca, and P by eGFR intervals Figure 3 describes the median values of Ca, P, and iPTH. Note the relative stability of serum Ca and P over the spectrum of eGFR values, until eGFR decreased to o20 ml/ min/1.73 m 2 . Median Ca and P values were within normal ranges, and increases in iPTH (465 pg/dl) began to occur at eGFR levels of approximately 45 ml/min/1.73 m 2 . Figure 4 describes the prevalence of abnormal values of Ca, P, and iPTH levels. There is a increase in the prevalence of (HPTH, iPTH 465 pg/ml) across declining eGFR levels. , similar to the point where the median value of 1,25 OH 2 D 3 begins to approach values deemed 'deficient' (22 pg/ml) when using the values in the lowest tertile for this population. This relationship was further explored by examining the prevalence of abnormalities within the population by eGFR deciles (Figures 6 and 7) . The prevalence of deficiency of 25(OH)D 3 remained relatively stable until eGFR fell below 30 ml/min/1.73 m 2 and appears to be dissociated from the HPTH prevalence. We then explored the prevalence of various combinations of abnormalities, and found that 49% of those with low 1,25 OH 2 D 3 levels had high iPTH, irrespective of 25(OH)D 3 levels; whereas, only 35% of those with low 25(OH)D 3 levels had high iPTH levels (Po0.05, w 2 test). Univariate analysis between patients with normal versus low values of 1,25 OH 2 D 3 revealed significant differences within the total population for all variables except age ( (Table 3) .
DISCUSSION
We describe here, in the largest observational study of an unselected cohort of patients with varying levels of kidney dysfunction, the prevalence of abnormalities of vitamin D metabolites, iPTH, and Ca and P. This study demonstrates a number of key findings, some of which corroborate previous work, and some of which are novel. Within this cohort, we attempted to better define 1,25 OH 2 D 3 deficiency, or more specifically, low values of 1,25 OH 2 D 3 . Thus we describe a high prevalence of low values of 1,25 OH 2 D 3 within this population, even at higher levels of eGFR than usually expected or has not been reported previously. Note that the low values are congruent with the low range of values as reported by the laboratory reference range. We also describe the prevalence of elevated iPTH levels, which increased significantly at eGFR values below 50 ml/min/1.73 m 2 . Importantly, neither of these changes was associated with demonstrable changes in serum Ca, P, or major differences in values of 25(OH)D 3 . The dissociation of HPTH from any significant changes in serum Ca and P in patients with a lower eGFR, whereas physiologically expected, underscores the need to assess this hormone level irrespective of these mineral metabolites. The late occurrence of hyperphosphatemia was not present in enough of the population to explain the high prevalence of HPTH in stage 4 disease.
The univariate predictors of low 1,25 OH 2 D 3 levels differed by eGFR values, but most interestingly, in the multivariate analysis, we demonstrated that DM, elevated UACR, and eGFR were independently associated with low levels of 1,25 OH 2 D 3 . There also seemed to be a strong association between low 1,25 OH 2 D 3 levels and the prevalence of HPTH. Although the Kidney Disease Outcomes Quality Initiative guidelines recommend iPTH testing in CKD patients at eGFR levels below 60 ml/min/1.73 m 2 , in general, such testing only occurs in a small number of patients, and these findings provide further support for those testing guidelines. Although PTH testing is clearly more practical at present, these findings also have implications for 1,25 OH 2 D 3 testing of individuals, given the biological relevance of that deficiency to HPTH, and the demonstration here that low levels of 1,25 OH 2 D 3 occur earlier in the course of eGFR decline than does elevations in iPTH levels. However, in the absence of longitudinal or outcome data Low serum 1,25 OH 2 D 3 occurs for a variety of reasons, and has been recently described as being more prevalent than previously thought in western populations. Although decreased renal 1-a hydroxylase in CKD is largely responsible for reduced circulating levels of 1,25 OH 2 D 3 , other potential factors may exist, which also suppress this hydroxylating enzyme. 11 In addition, low levels of the 25(OH)D 3 substrate may contribute to decreased levels of 1,25 OH 2 D 3 production, particularly in CKD patients with nephrotic range proteinuria. 12 One recent survey noted that 86% CKD patients (n ¼ 43) had inadequate 25(OH)D 3 levels (o30 ng/ ml), which has been previously defined by others. 13, 14 In our study, we also found that although many subjects had inadequate 25(OH)D 3 levels, only 12% were frankly deficient in 25(OH)D 3 deficient (o15 ng/ml). In addition, our large sample allowed us to determine that the relationship between 25(OH)D 3 and 1,25 OH 2 D 3 was not significant (R 2 ¼ 0.3666, P ¼ 0.3433 at eGFRo60 ml/min), which is consistent with Ishimura's observation; 15 and while statistically significantly different among the eGFR groups, the values were of questionable clinical significance (4-5 ng/ml). In this analysis, the relationship between serum 25(OH)D 3 with elevated iPTH and decreased GFR levels was less relevant than that of 1,25 OH 2 D 3 . This finding may have therapeutic ramifications as recent Kidney Disease Outcomes Quality Initiative guidelines currently suggest the use of ergocalciferol (vitamin D2) as the initial treatment for HPTH in CKD stage 3 and 4. 16 However, the findings herein of an early low levels of 1,25 OH 2 D 3 and some preliminary data that show that this treatment regimen may not effectively suppress PTH, 17 may require that those recommendations are revisited.
This study had several limitations. The patient ages were weighted to older individuals (71% of the sample was over 65 years old) and although a large proportion of CKD patients fall within this age range, these data may not be generalizable to patients between 40 and 65 despite their inclusion in the sample. The results are cross-sectional analyses, thus causal relationships between dependent variables (kidney function) and independent variables (vitamin D metabolites, iPTH, Ca, and P) cannot be defined. No longitudinal data has been reported here, thus relationships between the variables and different eGFR levels may change over time in different individuals. In addition, kidney disease was defined by a single creatinine measure used to estimate the eGFR. In fact 22% of the cohort changed 'classification' within the time period of screening and enrollment into the study, further underscoring the problems with defining populations based on single values without accompanying urine tests or clinical data. Nonetheless, the majority (78%) of the population did have persistent decreases in their kidney function, within 18 It is also known that 1,25-dihyroxyvitamin D levels are indirectly associated with serum renin levels in hypertensive subjects, 19 a finding that was recently corroborated in vitamin D receptor knockout mice. 20 Elevated PTH is known to cause cardiomyocyte damage in animals with CKD 21 and parathyroidectomy in dialysis patients is associated with reductions in left ventricular hypertrophy 22 and in cardiovascular mortality. 23 Thus, taken together we may speculate that low 1,25 OH 2 D 3 and elevated iPTH levels in CKD stage 3 and 4 may contribute to the high prevalence of cardiovascular and advanced renal disease seen in these populations. In addition, the independent association between low 1,25 OH 2 D 3 and high UACR may support the observed anti-proteinuric effect of active vitamin D in CKD patients. 24 Further long term data relating the levels to outcomes, and ulitmately a randomized controlled trial examining the impact of activated vitamin D on cardiovascular outcomes should be undertaken.
In summary, we found, in a large, unselected population that serum 1,25 OH 2 D 3 levels decline early in CKD before significant elevations in PTH are observed. Hypocalcemia and hyperphosphatemia, when and if they occur, are noted in the later stages of CKD. Future research should be directed toward attempting to further describe the relationship between vitamin D levels, eGFR and other factors related to clinically meaningful outcomes, by testing the impact of early interventions with activated vitamin D therapy.
MATERIALS AND METHODS
Study design SEEK is a prospective, community-based, non-interventional, prospective cohort study designed to examine the prevalence of abnormalities in serum iPTH, vitamin D, Ca, and P in patients with CKD. To be eligible for the study, patients had to be older than 40 years of age and to be an established member of the investigator's practice. Investigators included primary care physicians, endocrinologists, cardiologists, and nephrologists. The required screening data consisted of a signed informed consent form, a Health Insurance Portability and Accountability Act (HIPPA) waiver, and a serum creatinine value obtained in the calendar year 2003 or 2004. One hundred fifty-three (153), US-based centers recruited patients for the study, following approval from a central institutional review board and or ethics committee. Patients enrolled in the study were equally distributed across the United States (Table 1) , and given that sun exposure would affect serum 25(OH)D 3 levels, study visits and first blood sample collections were scheduled from June 2004 to October 2004, when sunlight intensity was consistent across the US. Patients enrolled were scheduled to visit the investigator's practice twice; one visit at baseline and one visit approximately 12 months later. Results of baseline interim cross-sectional analyses are described here.
Patient population
Following informed consent and screening, patients were enrolled if they had an eGFR o60 ml/min, as determined by the simplified Variables of interest and methods of measurement Medical history, medications, blood and urine samples were collected at study visit 1 (baseline). Blood was collected for serum creatinine, iPTH, 25(OH)D 3 , 1,25 OH 2 D 3 , Ca, P, albumin, and bone alkaline phosphatase. Total Ca was corrected for serum albumin using the equation: Calcium ¼ Ca þ 0.8 (4.0 albumin). All samples were run at a central laboratory (Quintiles Laboratories, Ltd., NJ, USA).
For the purposes of this study, the key variable of interest was the distribution of 1,25 OH 2 D 3 values. Both 25(OH)D 3 and 1,25 OH 2 D 3 were determined using the DiaSorin radioimmunoassay kit (Stillwater, MN, USA). Calcium, P, and creatinine were analyzed with a routine autoanalyzer. Serum iPTH was determined by a chemiluminescence assay (DPC, Los Angeles, CA, USA). The lab references are 10-65 pg/ml for iPTH, 8-60 ng/ml for 25(OH)D 3 and 25-65 pg/ml for 1,25 OH 2 D 3 .
Statistical analyses
Descriptive statistics of continuous variables are presented as means with s.d. or medians, depending on the distribution of the variable. Categorical variables are presented as distributions (i.e., frequencies and percentages). Estimated GFR was used as both a continuous and categorical variable, with intervals of 10 ml/min forming eight categories. The statistical significance of differences in the measured variables between subgroups was tested with the Pearson w 2 test for categorical analysis, and the t-test or the Wilcoxon rank sum test, where appropriate, for continuous variables.
Multivariable regression analyses were performed to investigate the predictors of levels of the different vitamin D metabolites and of iPTH in the context of this population. Variables included in the model were age, gender, ethnicity, DM, UACR, eGFR, Ca, and P.
Data are presented in both continuous and categorical format, so as to ensure interpretability for both clinical investigators and for clinicians.
Statistical analyses were performed using SAS software, version 8.01 (SAS Institute, Cary, NC, USA).
